Trending Topic

3d illustration of human body liver
12 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise from the biliary epithelium of the small ducts in the periphery of the liver […]

Othman Al-Sawaf, ASH 2020 – Venetoclax-obinutuzumab and the CLL14 Trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 15th 2021

Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.

Questions

  1. How is minimal residual disease used as a prognostic tool in chronic lymphocytic leukemia (CLL)?
  2. What were the aims and the rationale behind the CLL14 trial?
  3. Could you give an overview of the design of the CLL14 trial and its findings? 
  4. How may these findings impact clinical practice?
  5. What are the next steps in the clinical development of CLL treatment?

Speaker Disclosures: Dr Othman Al-Sawaf has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup